CXCR4 and breast cancer: We also identified PDGFRα as an effector that mediates CXCR4-induced EMT, suggesting that targeting the CXCR4-PDGFRα-PI3K pathway may be beneficial to NT21MP-reversed drug resistance in breast cancer.